As of Q4'25 (2025-08-31), ACN reported SG&A Expenses of $2.95B USD, while R&D Expenses remained at $0 USD. This marks the highest SG&A expense observed in the covered period, with no allocation to R&D throughout. From Q2'23 to Q4'25, ACN's operating expenses have been entirely composed of SG&A, consistently ranging between $2.65B and $2.95B USD per quarter. The data shows a generally stable but gradually increasing trend in SG&A expenses, with minor fluctuations and a notable peak in Q4'25. The absence of R&D spending indicates a continued focus on administrative and selling activities rather than research and development investment during this timeframe.